Literature DB >> 8830783

Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

G Deng1, S A Curriden, S Wang, S Rosenberg, D J Loskutoff.   

Abstract

Induction of the urokinase type plasminogen activator receptor (uPAR) promotes cell adhesion through its interaction with vitronectin (VN) in the extracellular matrix, and facilitates cell migration and invasion by localizing uPA to the cell surface. We provide evidence that this balance between cell adhesion and cell detachment is governed by PA inhibitor-1 (PAI-1). First, we demonstrate that uPAR and PAI-1 bind to the same site in VN (i.e., the amino-terminal somatomedin B domain; SMB), and that PAI-1 competes with uPAR for binding to SMB. Domain swapping and mutagenesis studies indicate that the uPAR-binding sequence is located within the central region of the SMB domain, a region previously shown to contain the PAI-1-binding motif. Second, we show that PAI-1 dissociates bound VN from uPAR and detaches U937 cells from their VN substratum. This PAI-1 mediated release of cells from VN appears to occur independently of its ability to function as a protease inhibitor, and may help to explain why high PAI-1 levels indicate a poor prognosis for many cancers. Finally, we show that uPA can rapidly reverse this effect of PAI-1. Taken together, these results suggest a dynamic regulatory role for PAI-1 and uPA in uPAR-mediated cell adhesion and release.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830783      PMCID: PMC2120994          DOI: 10.1083/jcb.134.6.1563

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  59 in total

1.  Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.

Authors:  D A Waltz; H A Chapman
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

2.  High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.

Authors:  R J Goodson; M V Doyle; S E Kaufman; S Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

3.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

Authors:  H Nekarda; M Schmitt; K Ulm; A Wenninger; H Vogelsang; K Becker; J D Roder; U Fink; J R Siewert
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

4.  Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.

Authors:  S Del Vecchio; M P Stoppelli; M V Carriero; R Fonti; O Massa; P Y Li; G Botti; M Cerra; G D'Aiuto; G Esposito
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

5.  The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.

Authors:  D Seiffert; G Ciambrone; N V Wagner; B R Binder; D J Loskutoff
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

6.  Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.

Authors:  M Ploug; V Ellis; K Danø
Journal:  Biochemistry       Date:  1994-08-02       Impact factor: 3.162

7.  Two human melanoma cell-line variants with enhanced in vivo tumor growth and metastatic capacity do not express the beta 3 integrin subunit.

Authors:  H Boukerche; M Benchaibi; O Berthier-Vergnes; G Lizard; M Bailly; M Bailly; J L McGregor
Journal:  Eur J Biochem       Date:  1994-03-01

8.  Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.

Authors:  D A Waltz; L Z Sailor; H A Chapman
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Authors:  J Grøndahl-Hansen; I J Christensen; C Rosenquist; N Brünner; H T Mouridsen; K Danø; M Blichert-Toft
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

10.  Loss of alpha 1 beta 1 and reduced expression of other beta 1 integrins and CAM in lung adenocarcinoma compared with pneumocytes.

Authors:  E Roussel; M C Gingras; J Y Ro; C Branch; J A Roth
Journal:  J Surg Oncol       Date:  1994-07       Impact factor: 3.454

View more
  96 in total

1.  Migration of keratinocytes through tunnels of digested fibrin.

Authors:  V Ronfard; Y Barrandon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

4.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

Authors:  Lawrence C Thompson; Sumit Goswami; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

5.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

6.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

7.  Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.

Authors:  Maud Jost; Catherine Maillard; Julie Lecomte; Vincent Lambert; Marc Tjwa; Pierre Blaise; Maria-Luz Alvarez Gonzalez; Khalid Bajou; Silvia Blacher; Patrick Motte; Chantal Humblet; Marie Paule Defresne; Marc Thiry; Francis Frankenne; André Gothot; Peter Carmeliet; Jean-Marie Rakic; Jean-Michel Foidart; Agnès Noël
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

8.  The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.

Authors:  Yu-Ran Na; Hana Im
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

Review 9.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

10.  Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.

Authors:  François Maquerlot; Stephane Galiacy; Michel Malo; Christophe Guignabert; Daniel A Lawrence; Maria-Pia d'Ortho; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.